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Abstract
Incorporating preclinical animal data, which can be regarded as a special kind of historical data, into
phase I clinical trials can improve decision making when very little about human toxicity is known. In
this paper, we develop a robust hierarchical modelling approach to leverage animal data into new phase
I clinical trials, where we bridge across non-overlapping, potentially heterogeneous patient subgroups.
Translation parameters are used to bring both historical and contemporary data onto a common dosing
scale. This leads to feasible exchangeability assumptions that the parameter vectors, which underpin the
dose-toxicity relationship per study, are assumed to be drawn from a common distribution. Moreover,
human dose-toxicity parameter vectors are assumed to be exchangeable either with the standardised,
animal study-specific parameter vectors, or between themselves. Possibility of non-exchangeability for
each parameter vector is considered to avoid inferences for extreme subgroups being overly influenced
by the other. We illustrate the proposed approach with several trial data examples, and evaluate
the operating characteristics of our model compared with several alternatives in a simulation study.
Numerical results show that our approach yields robust inferences in circumstances, where data from
multiple sources are inconsistent and/or the bridging assumptions are incorrect.
Key words: Bayesian hierarchical models; Bridging; Historical data; Phase I clinical trials; Robustness.
1 Introduction
Bridging strategies are increasingly being used in the paradigm of global drug development (Huang et al.,
2012; Li and Wang, 2012; Tsong, 2012; Viergever and Li, 2015), aiming to minimise duplication of clinical
research without disregarding heterogeneity between patient groups. Bridging studies may be conducted
in a new geographic region such as Japan to evaluate similarity of the performance, typically with respect
to efficacy, of a medicine which has likely been approved in other parts of the world, for instance, Europe,
based on a complete clinical drug development program. The International Conference on Harmonisation
(ICH) E5 Guideline (1998, 2006) discussed whether and when trial data generated in an ‘original’ region
can be leveraged to support the evaluation of drug activities in a new region, where a sponsor is seeking
registration. The degree of borrowing, ranging from none to full, is a matter of negotiation between the
sponsor and the local health authorities. Bridging strategies can mitigate the drug lag problem (de Haen,
1975; Ueno et al., 2013; Wileman and Mishra, 2010), and expedite patient access to new medicines.
Over the past few decades, the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan pro-
moted synchronisation of clinical drug development in Japan and other countries (PMDA, 2007). The
agency encourages domestic sponsors to participate in global phase I dose-finding studies, which has led
to a number of bridging studies conducted in the early phase; see, for example, Ogura et al. (2014). In
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this paper, we will focus on the design and analysis of phase I bridging studies, which aim to support
estimation of the maximum tolerated dose (MTD) in a new geographic region or patient subgroup. We
would thus like to leverage dose-toxicity data available in other but relevant studied populations. In this
setting, both intrinsic factors such as a patient’s genetic make-up, and extrinsic factors such as diagnostic
criteria as well as environmental exposures, can result in a different MTD across the regions or patient
subgroups. However, a review of 54 phase I oncology trials, conducted at the National Cancer Center
Hospital in Japan between 1995 and 2012 (Mizugaki et al., 2015), found evidence of a small between-region
heterogeneity in the toxicity profile of single cytotoxic agents.
Several model-based designs have been proposed for phase I clinical trials to address concerns about
differences between patient subgroups. Liu et al. (2015) develop a bridging continual reassessment method
(CRM) procedure that uses the dose-toxicity data from a completed historical trial to generate multiple
sets of ‘skeleton’ probabilities for a new trial in another geographic region. The authors then use the
Bayesian model averaging (Yin and Yuan, 2009) to reconcile this information. Takeda and Morita (2018)
present a Bayesian dose-escalation procedure which dynamically leverages information from a historical
study. Before the new trial begins, historical trial data are used to formulate a weakly informative prior
for the parameter of a functional dose-toxicity model employed by the CRM for dose recommendations;
so-called weakly informative because the prior effective sample size (Morita et al., 2008) is considerably
smaller than the anticipated sample size of the new trial. Historical and new trial data are then linked
through a ‘historical-to-current’ parameter, which reflects the degree of agreement between studies.
Alternatively, relevant ‘complementary-data’ (or co-data for short) (Neuenschwander et al., 2016a)
can be drawn from other phase I clinical trials run concurrently to the trial of interest, or one could
leverage data on a related patient subgroup enrolled in the same trial. O’Quigley et al. (1999) propose
a two-sample CRM to draw inferences about the MTDs for two non-overlapping groups of patients si-
multaneously. A shift model has been further discussed in the context of bridging studies by O’Quigley
and Iasonos (2014), which constrains the recommended dose in the second subgroup to be identical to,
or several levels shifted away the estimate in the first subgroup. Wages et al. (2015) extended this shift
model to design a phase I/II trial of stereotactic body radiation therapy, where uncertainty surrounding
the ‘true shift’ is tacitly concerned. These authors have restricted attention to the scenario where co-data
are exclusively the human toxicity data, collected from other subgroups. However, no phase I clinical
trial is planned in a vacuum: preliminary data characterising the toxicity profile of the drug will typically
be available in animals, as is required by regulatory authorities (USFDA, 2005). It thus appears to be
appealing to use this information, such that dose recommendations at early stages of the trials can be
backed up with sufficient evidence (Zheng and Hampson, 2019; Zheng et al., 2019).
Zheng et al. (2019) propose a Bayesian hierarchical model to leverage data from multiple animal
species in a phase I oncology trial, which will be performed in a homogeneous patient group, to support
the interim and final dosing recommendations. In this paper, we extend their approach to accommodate
the circumstances where the study population may involve heterogeneous patient subgroups. Specifically,
the robust extention proposed in this paper can augment a phase I bridging trial with co-data, which
may comprise (i) data from completed preclinical animal studies, (ii) concurrent external data from either
completed or ongoing trials conducted in related patient subgroups (e.g., patients from other geographic
regions). When the intrinsic and extrinsic factors arising from ethnicity would modify the dose-toxicity
relationship, our model will estimate the MTD specific to the regions.
The remainder of this paper is structured as follows. In Section 2, we develop a robust Bayesian
hierarchical model to leverage animal data into phase I trials, which can address potential between-
subgroup heterogeneity. In Section 3, we show several illustrative examples using our methodology to
improve decision making in phase I trials with co-data. In Section 4, we perform a simulation study to
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evaluate the operating characteristics of dose-escalation trials following the proposed design in comparison
with several alternatives. Finally, we draw conclusions and look towards future research in Section 5.
2 Bayesian hierarchical modelling for data from heterogeneous sources
In this section, we generalise the Bayesian model of Zheng et al. (2019) to leverage available animal data
and dose-toxicity data from different human subgroups into new phase I clinical studies.
Suppose that at the time of planning a phase I clinical trial, M preclinical studies have been performed
in K animal species, labelled S1, . . . , SK . For i = 1, . . . ,M , animal study i tested a total of Ji doses
contained in set Di = {di1, . . . , diJi ; dit1 ≤ dit2 for 1 ≤ t1 ≤ t2 ≤ Ji}. On receiving dose dij ∈ Di, an
animal experiences a dose-limiting toxicity (DLT) with probability pij and no DLT with probability 1−pij .
Let nij and rij be the number of animals that received dose dij and the number that experienced a DLT,
respectively. We assume a monotonic increasing relationship between pij and dij , which can be adequately
described by a two-parameter logistic regression model (Neuenschwander et al., 2008; Whitehead and
Williamson, 1998):
rij |pij , nij ∼ Binomial(pij , nij), for j = 1, . . . , Ji,
logit(pij) = θ1i + exp(θ2i) log(δAidij/dRef),
(1)
where δAi is a translation parameter mapping animal doses onto an equivalent human dosing scale. Zheng
et al. (2019) propose placing a tailored log-normal prior on δAi to account for the intrinsic differences
between the toxicity profile of the drug in animal species Ai ∈ {S1, . . . , SK} and humans. Thus, model
parameters θi = (θ1i, θ2i) describe the dose-toxicity relationship (equivalently) in humans. In Model (1),
dRef is a reference dose invariant across all dose-toxicity studies, which is often chosen to be the likely
human MTD.
Random-effects distributions are stipulated on the second level of the hierarchical model to enable
information sharing between animal studies of the same species:
θi|µAi ,Ψ ∼ BVN(µAi ,Ψ), (2)
with
µAi =
(
µ1Ai
µ2Ai
)
and Ψ =
(
τ21 ρτ1τ2
ρτ1τ2 τ
2
2
)
for Ai ∈ {S1, . . . , SK}. Variances in Ψ reflect the magnitude of between-study heterogeneity within
an animal species. A ‘supra-species’ random effects distribution is introduced to facilitate borrowing of
information across different animal species. That is, for species Sk, k = 1, . . . ,K,
µSk |m,Σ ∼ BVN(m,Σ), (3)
with
m =
(
m1
m2
)
and Σ =
(
σ21 κσ1σ2
κσ1σ2 σ
2
2
)
.
This ‘supra-species’ random-effects distribution accounts for the differences between toxicity parameters
in different species which are not addressed by the translation parameters δS1 , . . . , δSK .
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We now focus on modelling the human toxicity data that will be collected from different human
subgroups. Suppose there are a total of L predefined, non-overlapping human subgroups and one trial only
is performed in each subgroup. To distinguish from the notation used for animal studies, we let ` = 1, . . . , L
index the new human trials wherein the doses d`j ∈ D` = {d`1, . . . , d`J` ; d`t1 ≤ d`t2 for 1 ≤ t1 ≤ t2 ≤ J`}
are to be evaluated, and let γ` = (γ1`, γ2`) be the counterpart of θi; that is, γ` underpins the dose-toxicity
relationship in human subgroup `. Model (1) is also applicable to describe the human toxicity data, only
that we will set the animal-to-human translation parameter δAi = 1 and introduce a subgroup-specific
parameter denoted by ` for subgroup `. For a phase I clinical trial ` = 1, . . . , L, the human toxicity data
can be described by
r`j |p`j , n`j ∼ Binomial(p`j , n`j), for j = 1, . . . , J`,
logit(p`j) = γ1` + exp(γ2`) log(`d`j/dRef),
(4)
where dRef is the same reference dose used in Model (1) and ` adjusts for the differences in toxicity arising
from the intrinsic and/or extrinsic factors across human subgroups. In particular, this parameterisation
maps the dose-toxicity profiles of different subgroups onto an ‘average’ human dosing scale. We regard
each ` as a random variable, on which we place a normal prior distribution N(1, ν
2
` ), further truncated
for positive real numbers only, due to the use of a logrithm.
Here, we use a truncated normal prior symmetric about the value 1 instead of a log-normal prior on `
as we do for the animal-to-human translation parameter δSk ’s. Because the dose-toxicity data collect from
each subgroup ` can appropriately be assumed on the ‘average’ human dosing scale. More importantly,
it gives equal probability mass on ` > 1 and 0 < ` < 1, which corresponds to the drug at the same dose
being more or less toxic than the average in subgroup `, respectively. To strictly ensure the symmetry,
the normal prior will be truncated for values bounded by 0 and Uν , which depends on the choice of ν`. An
example is to place a normal prior N(1, 0.2552) truncated to fall within (0, 2) on each `, such that the
95% probability mass is concentrated on the interval [0.5, 1.5]. This indicates the region-specific MTDs,
if divergent, are expected to have less than 0.5-fold change between one another. Our stipulation here is
consistent with the general consensus that the toxicity risk would rarely be more than doubled in another
ethnic subgroup if the bridging assumption is correct.
Following Neuenschwander et al. (2016a) who allow for the possibility of more than one exchangeability
distribution, our model accommodates two exchangeability scenarios for γ1, . . . ,γL. That is, a) parameters
of animal and human dose-toxicity relationships are exchangeable with each other; and b) human dose-
toxicity parameters are exchangeable only with those of other human subgroups. For human subgroup
` = 1, . . . , L, we stipulate that
(i) with prior probability w`Sk for k = 1, . . . ,K:
γ`|µSk ,Ψ ∼ BVN(µSk ,Ψ);
This represents exchangeability between γ` and the study-specific parameters θi relating to animal
species Sk.
(ii) with prior probability w`H:
γ`|µH,Φ ∼ BVN(µH,Φ), (5)
so that γ` is exchangeable only with the parameter vectors of the other human subgroups and where
µH =
(
µ1H
µ2H
)
and Φ =
(
τ23 ητ3τ4
ητ3τ4 τ
2
4
)
;
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(iii) with prior probability w`R = 1−
∑
k w`Sk − w`H:
γ` ∼ BVN(m0`, R0`),
so that γ` is non-exchangeable with any other dose-toxicity parameters.
Before the conduct of a phase I trial in subgroup `, we need to pre-specify the prior probabilities
w`S1 , . . . , w`SK , w`H and w`R. The judgements of translational scientists or pharmacologists will be
valuable. Stipulating a large w`Sk or w`H reflects a high level of prior confidence in the relevance of data
from animal species Sk or in the bridging assumption.
This second ‘human only’ exchangeability distribution has its own covariance matrix Φ. This is be-
cause the degree of heterogeneity between study-specific dose-toxicity parameters in humans may be quite
different to the level of heterogeneity between study-specific parameters in animals or the variations across
species, captured by Ψ and Σ, respectively. When animal data have very limited predictability of the
human toxicity yet the human toxicity data between themselves share considerable commonality, our ro-
bust hierarchical model will lead to large posterior probabilities attributed to the (K + 1)th ‘human only’
exchangeability distribution. For additional robustness, the model assigns positive prior probabilities w`R
to the case that each γ` is not exchangeable with any other parameter vectors. When the dose-toxicity
relationship of a human subgroup appears to be an outlier, that is, is dissimilar to that of any other
human subgroups or animal species, the dose-toxicity parameters can be estimated based on their own
independent prior BVN(m0`, R0`).
To complete our Bayesian model, we now specify priors for other parameters. Weakly informative
priors are placed on the hyperparameters of the random effects distributions in Model 3 and Model 5.
The weakly informative priors used in subsequent sections are chosen so that each human toxicity risk p`j
has a wide 95% prior credible interval (Gelman et al., 2008). For the ‘supra-species’ population means
m = (m1,m2), we set m1 ∼ N(b1, s21) and m2 ∼ N(b2, s22). The same normal priors are used for µ1H and
µ2H, respectively. Priors for the variance parameters should reflect opinion on the degree of between-source
heterogeneity. Here, we propose setting
τ1 ∼ HN(z1), τ2 ∼ HN(z2), τ3 ∼ HN(z3), τ4 ∼ HN(z4),
σ1 ∼ HN(c1), σ2 ∼ HN(c2), ρ ∼ U(−1, 1), κ ∼ U(−1, 1), η ∼ U(−1, 1),
(6)
where HN(z) denotes a half-normal distribution formed by truncating a normal distribution N(0, z2)
to fall within (0,∞). This robust Bayesian hierarchical model can be fitted using Markov chain Monte
Carlo. We provide the OpenBUGS (Lunn et al., 2009) code in Appendix A for the implementation of our
Bayesian analysis model.
3 Illustrative example
In this section, we apply the robust Bayesian hierarchical model proposed in Section 2 to a hypothetical
trial example based on a real trial, which aimed to characterise the toxicity profile of GSK3050002 (Glax-
oSmithKline, 2016), an antibody for treating patients with psoriatic arthritis. The original trial enrolled
a total of 49 human subjects exclusively recruited from the United Kingdom, but we assume that two
hypothetical phase I trials (labelled T1 and T2) are to be performed in two geographic regions, R1 and
R2, respectively. For illustrative purposes, we suppose the trial T2 will be performed in region R2 after
the trial data of T1 in R1 are made available. The co-data for trial T2 thus comprise the data of trial T1
and animal studies where possible. The choice of animal species, animal doses and human doses for our
numerical studies are informed by the real GSK phase I clinical trial. For present purposes, the principal
aim of these hypothetical trials is to estimate a region-specific MTD, defined as the dose associated with
a risk of DLT of 25%.
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3.1 Hypothetical preclinical data and predictive priors for human toxicity
According to the protocol of GSK3050002 (GlaxoSmithKline, 2018), preclinical toxicity studies have been
performed in monkeys and rats. Moreover, monkeys were thought to be the most relevant animal species
for predicting toxicity in humans of this drug. In the two real monkey studies, doses 1, 10, 30, 100 mg/kg
were tested on 4 – 12 monkeys per dose group. From the trial protocol, it was not possible to identify
what dose levels were used in rats, nor the exact number of rats treated, nor the number of toxicities
observed. We therefore simulate plausible animal datasets based on the limited information available,
and use these simulated data to obtain predictive priors for the human toxicity at doses contained in set
D` = {0.1, 0.5, 1, 5, 10, 20} mg/kg, which will be evaluated in trials T1 and T2. The simulated animal data
are represented in Figure S1 of the Web-based Supplementary Materials.
Throughout, we set dRef = 5 mg/kg and use the priors as follows. We consider m1 ∼ N(−1.099, 1.982)
and m2 ∼ N(0, 0.992) for the ‘supra-species’ population means as well as for the elements of µH, and
σ1 ∼ HN(1) and σ2 ∼ HN(0.5) for the variances that permit sharing of information across animal species.
We assume moderate-to-substantial between-study heterogeneity between animal studies of the same
species would make sense, and therefore let τ1 ∼ HN(0.5), τ2 ∼ HN(0.25). Further, we assume small-to-
moderate heterogeneity between ethnic subgroups, captured by τ3 ∼ HN(0.25), τ4 ∼ HN(0.125). Here,
we stipulate a half-normal prior HN(z) with smaller z for the slope than that for the intercept, because we
desire to borrow more in terms of the shape rather than the location of the dose-toxicity curves (Kamrin,
1988). Following Zheng et al. (2019), we set δRat ∼ LN(−1.820, 0.3232) and δMonkey ∼ LN(−1.127, 0.2732)
to translate the animal data onto a common human scale.
For a robust inference under scenarios of data inconsistency, the non-exchangeability distributions
BVN(m0`, R0`) are specified for each trial `, independently. To be more specific, we setm01` ∼ N(−1.099, 22)
and m02` ∼ N(0, 12), with a zero correlation between m01` and m02`. By specifying the prior probability
of exchangeability as 1 to a specific animal species and retaining the rest as 0, predictive priors on toxicity
p`j for each phase I trial can be obtained based on animal data of a single species. For example, to
see how human toxicity may be predicted by the monkey datasets, we may fix w`Rat = 0, w`Monkey =
1, w`H = 0, w`R = 0. When we set w`R = 1 and retain the rest as 0, no animal data will be used, nor
are we making an assumption of bridging. Figure 1 presents the key summaries of such predictive priors
by the source of information. This would be useful to examine whether our Bayesian model can borrow
(discount) information quickly from a particular species, given the data consistency (inconsistency).
[Figure 1 about here.]
As we can see, the rat and monkey data predict 1 mg/kg and 5 mg/kg as doses highly likely to result
in a DLT risk close to 25% in a human trial. After translation of the animal doses, rat data are mainly
projected on the low doses of D`. Predictive priors obtained solely from rat data are thus more diffuse at
high doses such as 10 mg/kg and 20 mg/kg, at which monkey data in contrast have produced predictive
priors for the DLT risks with narrower credible intervals. Patients recruited in regions R1 and R2 are
predicted as having similar DLT risks based on the animal data. This is because the same prior proba-
bilities w`Sk , w`H and w`R, as well as the same truncated normal prior on `, have been chosen for each
human trial ` at the outset.
We obtain marginal predictive priors for the DLT risk in humans,by allocating prior weights to dif-
ferent animal species on the basis of their a priori predictability of the human toxicity. For trial T1, we
stipulate w1Rat = 0.2, w1Monkey = 0.6, w1H = 0 and w1R = 0.2. No prior probability has been allocated to
the exchangeability distribution for bridging across patient subgroups, because trial T2 has not yet started,
and the co-data for T1 are exclusively from animal studies. We note this is the Bayesian model proposed
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by Zheng et al. (2019), suitably for leveraging animal data to one homogeneous patient group. Figure
S2 of the Supplementary Materials gives summaries about the marginal predictive priors that synthesise
information across animal species. As soon as the trial T2 begins, we let the (K + 1)th exchangeability
component come into play. For illustration, we set w2Rat = 0.1, w2Monkey = 0.5, w2H = 0.2 and w2R = 0.2
to leverage both animal data and the T1 trial data, the human data from region R1, into trial T2.
We consider characterising each dose d`j ∈ D` with three interval probabilities; specifically, a dose
may lead to patients being (i) underdosed, if the DLT risk is less than 0.16, (ii) properly dosed, if the
DLT risk fall within the target interval [0.16, 0.33), and (iii) overdosed, if the DLT risk is greater than
0.33 (Neuenschwander et al., 2008). In this data example, we suggest choosing 0.1 mg/kg to be the safe
starting dose for the first-in-man trial T1, given P(p11 < 0.16|Y 1, . . . ,Y 5) = 0.872. Wherease, the safe
starting dose for trial R2 will be determined based on both the animal data and the western human
toxicity data with a similar approach.
It will be helpful to assess the effective sample size (ESS) (Morita et al., 2008) about the predictive
priors before using them. Before the conduct of human trials T1 and T2, we approximate each marginal
predictive prior for DLT risk per dose by beta distributions with parameters a and b, for the convenience
of calculating the ESS as (a + b). The parameters a and b are determined by matching the first two
moments of a Beta(a, b) with the original marginal predictive priors, obtained based on animal data for
each p`j . Table S1 of the Web-based Supplementary Materials reports the computed ESSs. Basically, the
animal data are equivalent to what would be acquired from 4.5 – 8.2 human subjects treated in each trial.
It may be worth to re-assess the ESSs after the completion of trial T1 to see how informative the co-data
for trial T2 would be.
3.2 Design and conduct of the phase I trials in different patient subgroups
Suppose that the phase I trials T1 and T2 are planned to have equal sample size, say, 24 patients. We
begin by recruiting patients in cohorts of size three to trial T1. After the toxicity responses have been
observed from the last cohort of trial T1, the trial T2 begins with the same trial structure. Specifically, the
co-data for trial T2 are from both the animal studies and trial T1. We use h` to index the cohort number of
trial T`, and Y (h`)T1 or Y
(h`)
T2 to denote the human toxicity data accrued up to the cohort h` of trial T1 or T2.
Recall that we have estimated dose 0.1 mg/kg as a suitable starting dose for patients in cohort h` = 1
of trial T1. For the subsequent patient cohorts h` ≥ 2 of the same trial, a dose will be recommended
according to the criterion:
dˆ
(h`)
T1 = max{d`j ∈ D` : P(p`j ≥ 0.33|Y 1, . . . ,Y 5,Y
(h`−1)
T1 ) ≤ 0.25}, (7)
where Y 1, . . . ,Y 5 represent the five hypothetical animal datasets collected from the rat and monkey
studies. The phase I trials will be terminated either after completion of treatment for all the 24 patients,
or for safety if the posterior risk of overdosing is too high. When the complete data of trial T1, denoted
by Y T1 , are made available, we start the trial T2 with dose
dˆ
(h`=1)
T2 = max{d`j ∈ D` : P(p`j < 0.16|Y 1, . . . ,Y 5,Y T1) > 0.85},
and a dose
dˆ
(h`≥2)
T2 = max{d`j ∈ D` : P(p`j ≥ 0.33|Y 1, . . . ,Y 5,Y T1 ,Y
(h`−1)
T2 ) ≤ 0.25}. (8)
to be recommended to patients in the subsequent cohorts. To prevent escalating doses too rapidly, addi-
tional constraints such as “never skipping a dose during the escalation” may be applied in practice. This
means, in our illustrative example, one cannot skip dose 0.5 mg/kg to recommend 1 mg/kg for patients
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in cohort h` = 2, even if the first three doses all comply with criteria (7) and (8).
[Figure 2 about here.]
Figure 2 shows two simulated realisations of trials T1 and T2. These data examples were simulated
under different scenarios for the human dose-toxicity relationship, basing dose recommendations on the
proposed Bayesian model. Specifically, subfigure (i) considers the scenario of divergent toxicity profiles
in each human subgroup, while subfigure (ii) assumes the two relationships are consistent. Prior spec-
ifications as well as the prior probabilities of exchangeability and non-exchangeability follows what was
described in Section 3.1. Figure 2 verifies that the choice of a safe dose to start with in trial T2 indeed
relies on the toxicity data accrued from the first trial T1. Reading subfigure (i) of Figure 2 together with
Figure 1, there seems to be no consistent animal data for the first-in-man trial T1 in scenario (i); moreover,
considerable heterogeneity exists between trials T1 and T2. Regardless of the sequential conduct of these
phase I trials, our Bayesian approach allows any inconsistent information from external sources to be
discounted quickly, leading to declaration of doses 20 mg/kg and 5 mg/kg as the region-specific MTDs.
On the completion of trial T1, we re-assess the ESSs before the start of trial T2. Table 1 lists the
corresponding ESSs for the marginal posteriors or priors for the human toxicity, given the hypothetical
T1 trial data simulated from scenarios (i) and (ii), respectively. From this, even when there exists fairly
rich information on human toxicity from a different patient subgroup, the predictive priors for trial T2
obtained using the proposed Bayesian model are very unlikely to dominate the analysis.
4 Simulation study
In this section, we compare the operating characteristics of phase I dose-escalation trials, conducted using
the proposed Bayesian hierarchical model or an alternative Bayesian model. The Bayesian analysis models
we consider are as follows.
• Model A is the proposed Bayesian model that leverages co-data from multiple sources;
• Model B discards animal data; human parameter vectors γ1 and γ2 are assumed fully exchangeable;
• Model C analyses trials T1 and T2 separately, without leveraging any animal data;
• Model D leverages animal data to trials T1 and T2, with w`Rat = 0.2, w`Monkey = 0.6 and w`R = 0.2,
respectively, but permits no borrowing across human subgroups;
• Model E analyses trial T1 without using any co-data, and trial T2 pooling data only from T1.
The prior specifications for Model A remain unchanged from Section 3.1. All the simulated T1 trials,
regardless of the analysis model, begin with the lowest dose 0.1 mg/kg. Simulated T2 trials begin with
dose 0.1 mg/kg, when implementing Models C and D. However, the choice of a safe starting dose for
T2 is conditional on both animal data and data from T1 trial data when using analysis Model A, and
solely on T1 trial data when using Model B or E. In these settings, we select as the starting dose for
trial T2 the highest dose d`j? that complies with P(p`j? < 0.16|Y 1, . . . ,Y 5,Y T1) > 0.85 for Model A, or
P(p`j? < 0.16|Y T1) > 0.85 for Model B or E. Model D is essentially the Bayesian model of Zheng et al.
(2019) for incorporating animal data into a phase I trial in a homogeneous human population. We note
that Model A simplifies to Model D if w`H = 0.
[Table 2 about here.]
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Each simulated phase I trial is performed in an adaptive manner: interim dose recommendations
are made according to criteria (7) and (8) for trials T1 and T2, respectively. Given the true probability
of toxicity per human dose listed in Table 2, we simulate the DLT outcomes of patients from a binary
distribution. We evaluate the properties of the Bayesian models under six scenarios, comprising cases
where there are conflicts across data sources, and cases where parameters in different subgroups are
exchangeable. Scenarios 1 and 6 represent two extremes. Only simulated trials with all 24 patients
treated and their toxicity outcomes observed will lead to a declaration of a region-specific MTD. At the
end of a complete trial in region R`, we declare as the MTD the dose
dˆ`M = arg min
d`j∈D′`
|p˜`j − 0.25|,
where p˜`j denotes the posterior median DLT risk at dose d`j , and D′` ⊆ D` contains all the doses that
were used to treat patients in the study, and also satisfy our overdose criterion. Simulations were run
in R (version 3.4.4) (R Core Team, 2017) using the package R2OpenBUGS (Thomas, 2017) based on
two parallel chains, each contributing 15 000 MCMC samples and sacrificing the first 5 000 iterations as
burn-in.
For each toxicity scenario, we simulated 1000 pairs of adaptive phase I dose-escalation trials in regions
R1 and R2 per Bayesian model. Results in the following were summarised by region. Averaging across
the simulated phase I trials, we reported the percentage of trials that were stopped early for safety, and
percentage of trials declaring a specific dose as MTD. In addition, we reported the average number of
patients that were allocated to each dose. This helps us to understand whether different Bayesian models
carry greater risks for patients’ safety particularly in scenarios of excessive toxicity, such as scenario 5.
[Figure 3 about here.]
Our primary interest lies in understanding the strength and weaknesses of the proposed Bayesian
model, which leverages animal data as well as human toxicity data from a different subgroup. We focus
here on the operating characteristics of Models A, B and D. Comparisons between Models A, C and E are
presented in Figure S3 and the complete numerical results in Table S2 of the Supplementary Materials.
From Figure 3, we see that Model A is able to beat the alternative analysis models across nearly all the
simulation scenarios. In scenarios 1 and 2, where animal data are highly predictive of the human DLT
risk, compared with Model B, Models A and D lead to a higher percentage of correct selection (PCS) and
a higher proportion of patients allocated to tolerable doses, with a DLT risks in the range [0.16, 0.33).
In scenario 1, DLT risks are identical across human subgroups. Comparing Models A and D, allowing
for information sharing across patient subgroups leads to an increase in the PCS for trial T2 from 16% to
45% in scenario 1. Borrowing across human subgroups offers smaller but still meaningful gains in PCS
in scenarios 2 and 3, when DLT risks are similar, but not identical, in the two regions. Due to the “no-
skipping-of-dose” restriction and a small sample size, it is challenging in scenario 4 to declare doses 20 and
10 mg/kg as the MTD in trials T1 and T2, respectively. Nevertheless, trials performed using Model A have
the highest PCS in regions R1 and R2. In particular, we see an increase of 25.3% in PCS and, averagely,
about 6 more patients treated at the true MTD of trial T2, comparing Model A with Model D in scenario 4.
In scenario 5, all the Bayesian analysis models adequately protect patients from receiving overly toxic
doses. Due to the use of animal data, Models A and D tend to treat more patients than Model B with
doses 0.5 and 1 mg/kg, which have human DLT risks exceeding 33%. However, the average number
of patients experiencing a DLT is not substantially higher than the number under Model B. Scenario 6
represents the case where the bridging assumption is incorrect. Comparing trial operating characteristics
under Model A with those under Models C and D (which make no assumption of bridging), we find our
approach can effectively discount information from trial T1 and so leads to a PCS which is comparable to
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that of Models C and D. Nevertherless, Model A allocates more patients (specifically, 6 more on average)
to dose 1 mg/kg than Models B and C in scenario 6.
Comparing Model A with Model B in scenarios 1 – 4, in which the bridging assumption is correct,
there is a clear benefit of leveraging preclinical animal data and allowing for the possibility of non-
exchangeability. In scenarios 1 – 3, Model B assigned more patients of trial T1 to dose 1 mg/kg than the
true MTD 5 mg/kg, due to the stated “no-skipping” dose-escalation constraint and our rule for defining
the MTD: only the administered doses are eligible to be selected as a MTD. Consequently, more trials
were ended with a safer dose being declared as the MTD. In contrast, Models A and D which make use of
animal data (of which the monkey data favour dose 5 mg/kg) helped faster escalation to the true MTD in
these scenarios. In scenarios 3 and 4, Model B experienced increasing difficulty distinguishing the region-
specific MTD particularly for trial T2 when the true MTDs are on the top of set D` and when differences
between human toxicity across regions were small. Indeed, the assumption of full exchangeability led to
excessive sharing of information between the two phase I clinical trials. In scenario 5, trial T1 conducted
using Model B were more likely to be stopped early for safety. Models A and B gave divergent operating
characteristics in scenario 6. As Model B tends to underestimate the toxicity in region R1 in such a
scenario (like scenario 4), too strong borrowing of information from T1 to T2 led to more T2 trials stopped
early than Models A and D. Focusing on Models A and D in scenario 6, using animal data provides
advantages for correctly selecting the MTD in each region. Whereas, Model A allocated about 6 – 7 more
patients to dose 1 mg/kg in trial T2 and more often incorrectly select this dose as MTD, compared with
Model D, as the loss of making an erroneous bridging assumption.
Referring to the Supplementary Materials, we can compare Model A with Models C and E in similar
ways. In particular, the improved operating characteristics when comparing Models A and C should be
interpreted as a mixture of benefit from using both animal data and appropriate bridging strategy. The
main disadvantage of Models C and E is that they are too extreme models for either not borrowing at
all or completely pooling the trial data of T1 for trial T2. We have also compared Models A – E with
respect to the posterior estimates of the dose-toxicity relationship in each human subgroup. Figure S4
of the Supplementary Materials show that Model A outperforms the others, providing very satisfactory
characterisation of the association on the termination of a phase I clinical trial. We additionally ran
simulations for a robust version of Model B with w`R = 0.20. Conclusions are similar with those written
in Neuenschwander et al. (2016a) and Zheng et al. (2019), and thus will not be repeated in this paper.
[Figure 4 about here.]
We introduced a bridging parameter ` into the human dose-toxicity model in the form of (4). Our
approach (Model A) maps animal data onto the equivalent human dosing scale for the incorporation into
human trials T1 and T2. With inclusion of a random ` after setting δAi = 1 for the human trials, the
bridging parameter may also be suggestive of whether animal data over- or under-predict the toxicity of
patients in a specific human subgroup. See Figure 4 for the boxplots of Model A in scenario 4, where
animal data from both rat and monkey studies have underestimated the toxicity in human subjects. We
observe both ` for trials T`, ` = 1, 2 shifted from the normal prior mean to take a value smaller than its
normal prior mean which is 1, such that the random-effects distributions (2) can explain some variability.
The smaller difference between the values of `, the more variability will be explained by the human
specific random-effects distribution BVN(µH,Φ). This can be perceived by the boxplots in scenarios 1
and 3 of Figure 4. When the boxplot is shifted to take a value larger than 1 (the normal prior mean), it
suggests animal data are likely to have overestimated the human toxicity, see for example scenario 2 for
trial T2. As in scenario 5 many simulated trials will be stopped early for safety while ` will be estimated
for a completed trial only, we will exclude the boxplots in this scenario for discussion. In contrast, the
parameter ` embedded in Model B exclusively addresses the intrinsic differences arising from ethnicity
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between patient subgroups. Within the same scenario, say, scenarios 1 and 3 where the bridging strategy
should better be implemented, ` for both trials T1 and T2 take values centring around 1 (the normal prior
mean). When the drug is more toxic to patients of regions R1 than R2, the boxplot of ` for trial T2 shifts
upwards to take larger values, see the boxplots in scenarios 2 and 6.
5 Discussion
Bridging studies have received considerable interest (Wadsworth et al., 2018), as fewer resources may be
needed to demonstrate drug behaviours by using relevant data from other subgroups, compared with the
approach of establishing an independent package of clinical drug development. To date, methodology to
extrapolate from foreign clinical data has been proposed mainly for phase II and phase III trials (Chow
et al., 2012; Hsiao et al., 2004; Tsou et al., 2012; Zhang et al., 2017). Discussion was limited on making
good use of co-data in phase I dose-escalation trials for informed decision making. Moreover, there appears
to be scant literature on regarding preclinical animal data as a special kind of co-data for human trials.
In this paper, we have presented a robust Bayesian hierarchical model for leveraging co-data, available
from both animal studies and phase I trials conducted in different patient subgroups, to improve the
mid-course dose recommendations as well as the estimation of the subgroup-specific MTD. Our model can
accommodate heterogeneity from various sources and lead to robust inferences. It down-weights co-data
effectively in scenarios of inconsistency with the new trial data, and improves operating characteristics in
scenarios of data consistency. For illustration, we presented several hypothetical data examples and the
simulation study with two phase I trials, assuming that they are planned in different geographic regions
and conducted one after the other. The proposed Bayesian approach, however, works equally well if the
phase I trials would have been run concurrently. In this case, each trial will be regarded as a stratum and
the interim dose recommendations will be based on accmulating data from the ongoing trials. We also
note there is no restriction on the number of phase I trials, for which we wish to base the decision making
on the co-data. Potentially, a large number of human subgroups can be advantageous for estimating the
between-trial heterogeneity, and therefore better determine the degree of borrowing in each human trial
T`, ` = 1, . . . , L.
Our Bayesian model presented in this paper is highly relevant with the development of early phase
basket trials (Psioda et al., 2019; Renfro and Sargent, 2017), where robust hierarchical models have been
considered for borrowing of information (Chu and Yuan, 2018; Neuenschwander et al., 2016b). Since our
approach can bridge across patient subgroups, it has the potential to be applied for analysing basket
trials. Historical data would have to be carefully chosen to formulate the exchangeability distributions.
It would also be worth refining the borrowing based on how similar the outcome data would be across
subgroups, drawing ideas from(Zheng and Wason, 2019).
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A OpenBUGS code for implemention
model{
# sampling model
# Mdoses: total number of doses tested in animal species
for(j in 1:MdoseA){
linA[j] <- theta[StudyA[j], 1]
+ exp(theta[StudyA[j], 2])*log(deltaA[Species[j]]*DoseA[j]/DoseRef)
logit(pToxA[j]) <- linA[j]
NtoxA[j] ~ dbin(pToxA[j], NsubA[j])
}
zero[1] <- 0
zero[2] <- 0
# theta = (theta[i, 1], theta[i, 2]) derived from each animal study are ready for the use
# on the equivalent human dosing scale
for(i in 1:NstudyA){
for(j in 1:MdoseH){
lin[i, j] <- theta[i, 1] + exp(theta[i, 2])*log(DoseH[j]/DoseRef)
}
# sp.ind[i]: index function to specify
# which animal species the Study i belongs to
theta[i, 1] <- mu.sp[sp.ind[i], 1] + re.A[i, 1]
theta[i, 2] <- mu.sp[sp.ind[i], 2] + re.A[i, 2]
re.A[i, 1:2] ~ dmnorm(zero[1:2], prec.Psi[1:2, 1:2])
# PInd[]: matrice of the trivial/non-trivial weights
# trivial weights for animals means 0 prob of NEX
# to assure theta_i are fully exchangeable withing the same species
sp.ind[i] ~ dcat(PInd[i, 1:n.sp])
}
# the K EX distributions based upon animal species clusters
for(k in 1:n.sp){
deltaA[k] <- exp(Prior.mn.delta[k] + Prior.sd.delta[k]*log.delta01[k])
log.delta01[k] ~ dnorm(0, 1)
mu.sp[k, 1] <- muA[1] + re.m[k, 1]
mu.sp[k, 2] <- muA[2] + re.m[k, 2]
re.m[k, 1:2] ~ dmnorm(zero[1:2], prec.Sigma[1:2, 1:2])
theta.predH[k, 1] <- mu.sp[k, 1] + re.h[k, 1]
theta.predH[k, 2] <- mu.sp[k, 2] + re.h[k, 2]
re.h[k, 1:2] ~ dmnorm(zero[1:2], prec.Psi[1:2, 1:2])
}
for(i in 1:n.sb){
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for(k in 1:n.sp){
mix.theta[i, k, 1] <- theta.predH[k, 1]
mix.theta[i, k, 2] <- theta.predH[k, 2]
}
mix.theta[i, (n.sp+1), 1] <- muH[1] + re.s[i, 1]
mix.theta[i, (n.sp+1), 2] <- muH[2] + re.s[i, 2]
re.s[i, 1:2] ~ dmnorm(zero[1:2], prec.Phi[1:2, 1:2])
mix.theta[i, (n.sp+2), 1:2] ~ dmnorm(Prior.mw[1:2], prec.sw[1:2, 1:2])
# pick theta
theta.star[i, 1] <- mix.theta[i, exch.ind[i], 1]
theta.star[i, 2] <- mix.theta[i, exch.ind[i], 2]
# latent mixture indicators:
exch.ind[i] ~ dcat(wMix[i, 1:(n.sp+2)])
for(ii in 1:(n.sp+2)){
each[i, ii] <- equals(exch.ind[i], ii)
}
# Update theta.star[i, 1:2] using the phase I trial data from various subgroups
for(j in 1:MdoseH){
linH[i, j] <- theta.star[i, 1]
+ exp(theta.star[i, 2])*log(epsilonH[i]*DoseH[j]/DoseRef)
logit(pToxH[i, j]) <- linH[i, j]
NtoxH[i, j] ~ dbin(pToxH[i, j], NsubH[i, j])
pCat[i, j, 1] <- step(pTox.cut[1] - pToxH[i, j])
pCat[i, j, 2] <- step(pTox.cut[2] - pToxH[i, j])
- step(pTox.cut[1] - pToxH[i, j])
pCat[i, j, 3] <- step(1 - pToxH[i, j])
- step(pTox.cut[2] - pToxH[i, j])
}
epsilonH[i] <- Prior.mn.epsilon[i] + Prior.sd.epsilon[i]*epsilon01[i]
epsilon01[i] ~ dnorm(0, 1)I(-3.921, 3.921)
}
# Hyperpriors for the human-specific population means muH[1:2]
muH[1] ~ dnorm(Prior.mH1[1], prec.mH1)I(-10, 10)
muH[2] ~ dnorm(Prior.mH2[1], prec.mH2)I(-5, 5)
prec.mH1 <- pow(Prior.mH1[2], -2)
prec.mH2 <- pow(Prior.mH2[2], -2)
# Hyperpriors for the ‘supra-spiece’ population means muA[1:2]
muA[1] ~ dnorm(Prior.mA1[1], prec.mA1)I(-10, 10)
muA[2] ~ dnorm(Prior.mA2[1], prec.mA2)I(-5, 5)
prec.mA1 <- pow(Prior.mA1[2], -2)
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prec.mA2 <- pow(Prior.mA2[2], -2)
# Hyperpriors for the covariance matrix, prec.Psi[1:2, 1:2]
prec.tau1 <- pow(Prior.tau.HN[1], -2)
prec.tau2 <- pow(Prior.tau.HN[2], -2)
tauA[1] ~ dnorm(0, prec.tau1)I(0.001,)
tauA[2] ~ dnorm(0, prec.tau2)I(0.001,)
covA.ex[1, 1] <- pow(tauA[1], 2)
covA.ex[2, 2] <- pow(tauA[2], 2)
covA.ex[1, 2] <- tauA[1]*tauA[2]*rhoA
covA.ex[2, 1] <- covA.ex[1, 2]
prec.Psi[1:2, 1:2] <- inverse(covA.ex[1:2, 1:2])
rhoA ~ dunif(Prior.rho[1], Prior.rho[2])
# Hyperpriors for the covariance matrix, prec.Sigma[1:2, 1:2]
prec.sigma1 <- pow(Prior.sigma.HN[1], -2)
prec.sigma2 <- pow(Prior.sigma.HN[2], -2)
sigma[1] ~ dnorm(0, prec.sigma1)I(0.001,)
sigma[2] ~ dnorm(0, prec.sigma2)I(0.001,)
covA.sig[1, 1] <- pow(sigma[1], 2)
covA.sig[2, 2] <- pow(sigma[2], 2)
covA.sig[1, 2] <- sigma[1]*sigma[2]*kappaA
covA.sig[2, 1] <- covA.sig[1, 2]
prec.Sigma[1:2, 1:2] <- inverse(covA.sig[1:2, 1:2])
kappaA ~ dunif(Prior.kappa[1], Prior.kappa[2])
# Hyperpriors for the covariance matrix, prec.Phi[1:2, 1:2]
prec.tau3 <- pow(Prior.tau.HN[3], -2)
prec.tau4 <- pow(Prior.tau.HN[4], -2)
tauH[1] ~ dnorm(0, prec.tau3)I(0.001,)
tauH[2] ~ dnorm(0, prec.tau4)I(0.001,)
covH.ex[1, 1] <- pow(tauH[1], 2)
covH.ex[2, 2] <- pow(tauH[2], 2)
covH.ex[1, 2] <- tauH[1]*tauH[2]*rhoH
covH.ex[2, 1] <- covH.ex[1, 2]
prec.Phi[1:2, 1:2] <- inverse(covH.ex[1:2, 1:2])
rhoH ~ dunif(Prior.rho[1], Prior.rho[2])
# Weakly-informative hyperpriors for the covariance matrix, prec.sw[1:2, 1:2]
cov.rb[1, 1] <- pow(Prior.sw[1], 2)
cov.rb[2, 2] <- pow(Prior.sw[2], 2)
cov.rb[1, 2] <- Prior.sw[1]*Prior.sw[2]*Prior.corr
cov.rb[2, 1] <- cov.rb[1, 2]
prec.sw[1:2, 1:2] <- inverse(cov.rb[1:2, 1:2])
}
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Figure 1: Summaries about the predictive priors for human toxicity, when using animal data from a single species (Panels A and B) or
no animal data at all (Panel C). Medians together with 95% credible intervals of the marginal predictive priors are plotted.
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Figure 2: Trial trajectory of hypothetical phase I trials performed in two geographic regions, in which trial data were simulated from
(i) a divergent scenario and (ii) a consistent scenario, respectively.
Table 1: Effective sample sizes of the marginal predictive posteriors (priors) for the DLT risk per dose, on the completion of trial T1
(start of trial T2), given the T1 trial data simulated from (i) a divergent scenario and (ii) a consistent scenario, respectively
Trial T1 Trial T2
d`1 d`2 d`3 d`4 d`5 d`6 d`1 d`2 d`3 d`4 d`5 d`6
0.1 0.5 1 5 10 20 0.1 0.5 1 5 10 20
Sc (i) Posterior/Prior means 0.028 0.046 0.059 0.107 0.144 0.199 0.070 0.114 0.144 0.273 0.361 0.438
Posterior/Prior std dev. 0.032 0.043 0.049 0.068 0.079 0.105 0.110 0.141 0.158 0.221 0.260 0.281
ESS 25.1 23.1 22.1 19.8 18.7 13.5 4.4 4.1 4.0 3.0 2.4 2.1
a 0.7 1.1 1.3 2.1 2.7 2.7 0.3 0.5 0.6 0.8 0.9 0.9
b 24.4 22.0 20.8 17.7 16.0 10.8 4.1 3.6 3.4 2.2 1.5 1.2
Sc (ii) Posterior/Prior means 0.047 0.092 0.128 0.315 0.418 0.508 0.074 0.123 0.156 0.300 0.396 0.483
Posterior/Prior std dev. 0.043 0.058 0.065 0.154 0.207 0.229 0.110 0.138 0.153 0.206 0.240 0.256
ESS 23.0 23.4 25.8 8.0 4.7 3.7 4.7 4.7 4.6 4.0 3.1 2.8
a 1.1 2.1 3.3 2.5 2.0 1.9 0.3 0.6 0.7 1.2 1.2 1.4
b 21.9 21.3 22.5 5.5 2.7 1.8 4.4 4.1 3.9 2.8 1.9 1.4
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Table 2: Simulation scenarios for the true probability of toxicity in humans for the phase I trials T1 and T2. The figure in bold indicates
the target dose closest to the true MTD in each region.
Trial T1 Trial T2
d`1 d`2 d`3 d`4 d`5 d`6 d`1 d`2 d`3 d`4 d`5 d`6
0.1 0.5 1 5 10 20 0.1 0.5 1 5 10 20
Scenario 1 0.01 0.03 0.10 0.25 0.34 0.47 0.01 0.03 0.10 0.25 0.34 0.47
Scenario 2 0.01 0.03 0.10 0.25 0.34 0.47 0.05 0.12 0.25 0.37 0.50 0.60
Scenario 3 0.01 0.03 0.10 0.25 0.34 0.47 0.01 0.03 0.07 0.15 0.25 0.37
Scenario 4 0.01 0.03 0.05 0.08 0.15 0.25 0.02 0.05 0.07 0.12 0.25 0.36
Scenario 5 0.25 0.34 0.47 0.55 0.65 0.75 0.40 0.50 0.60 0.70 0.80 0.90
Scenario 6 0.01 0.03 0.05 0.08 0.15 0.25 0.10 0.25 0.36 0.50 0.60 0.68
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Figure 3: Operating characteristics of the adaptive phase I dose-escalation trials in regions R1 and R2, conducted and analysed using
Models A, B and D. The vertical black solid (dotted) line indicates the true MTD in the first-in-man trial T1 (trial T2) in each simulation
scenario.
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Figure 4: Boxplots that depict the posterior means of the region parameter ` estimated by the end of completed trials, designed using
Model A or Model B. The horizontal black line represents the prior mean of `.
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A. THE SIMULATED ANIMAL DATA AND PREDICTIVE PRIORS FORHUMAN TOXICITY
Figure S1 represent the simulated animal data used for the numerical studies. The height of the
bar represents the number of animal subjects treated, and the height of the dark grey segment
counts the number of toxicity. Doses listed in brown are those administered to either rats and
monkeys, which are translated onto an equivalent human dosing scale in black. Projections are
made by scaling animal doses using the prior median of δRat or δMonkey.
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Figure S1: Hypothetical preclinical data in rats and monkeys, simulated for the illustrative examples as well as the simulation study.
With the simulated animal data and the priors specified in Section 3.1, we further obtain
the marginal predictive priors that are shown graphically in Figure S2. We approximate these
marginal predictive priors with a series of Beta(a, b) distributions and report the prior effective
sample size (ESS) for the predicted human toxicity at each dose in Table S1.
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Figure S2: Summaries about the robust, marginal predictive priors for human toxicity based on the animal data. Panel A shows
median and 95% credible interval of the marginal predictive prior for human toxicity at each dose. Panel B presents the prior interval
probability of overdose, and Panel C displays prior densities for the risks of toxicity at potential starting doses.
Table S1: Effective sample sizes of the marginal predictive priors for the DLT risk per dose, obtained before trial T1 begins by fitting
the robust Bayesian model, which translates the animal data onto an equivalent human dosing scale.
Trial T1 Trial T2
d`1 d`2 d`3 d`4 d`5 d`6 d`1 d`2 d`3 d`4 d`5 d`6
0.1 0.5 1 5 10 20 0.1 0.5 1 5 10 20
Prior means 0.093 0.148 0.182 0.302 0.374 0.444 0.093 0.148 0.182 0.302 0.374 0.444
Prior std dev. 0.096 0.120 0.133 0.172 0.195 0.211 0.096 0.120 0.133 0.172 0.195 0.211
ESS 8.2 7.7 7.4 6.2 5.1 4.5 8.2 7.7 7.4 6.2 5.1 4.5
a 0.8 1.1 1.3 1.9 1.9 2.0 0.8 1.1 1.3 1.9 1.9 2.0
b 7.4 6.6 6.1 4.3 3.2 2.5 7.4 6.6 6.1 4.3 3.2 2.5
B. SIMULATION RESULTS THAT ARE NOT PRESENTED IN THEMAIN PAPER
In the main mauscript, we have compared Model A (the proposed approach) with Models B and
D and interpreted the results in terms of benefit attributed to either using the robust bridging
strategy (Model A versus Model B) or animal data (comparing Model A and D). Here, we present
additional simulation results in Figure S3 to compare our Model A with Models C and E, which
does not use co-data at all and completely pools the data from trial T1 to T2. Numerical results of
the complete comparison based on Models A – E are listed in Table S2.
In scenarios 1 – 3 when the bridging assumption is correct and/or animal data provide high
predictability of human toxicity, it is evident that Model A leads to significantly increased PCS
and allocates more patients to the true MTD in both regions R1 and R2. For example, comparing
Models A and C, the PCS was increased from 14.7% to 42% in scenario 1 for trial T1 due to the use
of animal data, and from 17% to 45% for trial T2 due to the use of animal data and correct bridging
strategy. Model E does not leverage animal data into trial T1 but completely pools in the T1 trial
data into trial T2. As a result, we observe that the PCS for trial T1 was much lower than that of
Model A in these scenarios, although a higher PCS is observed in scenario 2 for pooling in the
consitent T1 trial data. Using trial data from other human subgroup by such completely pooling
approach could be harmful, which is evidenced by the results in scenario 6. Comparing Model A
and Model E, we see that the latter allocated much more patients to excessively toxic doses which
are 5, 10 and 20 mg/kg in this scenario, and more often decleared dose 1 mg/kg as the MTD. This
is not surprising: pooling in the T1 trial data means we suppose patients in regions R1 and R2 are
exchangeable, and Model E would consequently underestimate the human toxicity in trial T2.
We now switch our focus to assessing the accuracy of the posterior point estimates based on
the Bayesian analysis models. As has been illustrated, leveraging co-data that are (in)consistent
with current trial data, should improve the accuracy of posterior estimates for the probability of
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Figure S3: Operating characteristics of the adaptive phase I dose-escalation trials in two geographic regions, conducted and analysed
using Models A, C, D. The vertical black solid (dotted) line indicates the true MTD in the western trial `? (eastern trial `) under each
simulation scenario.
toxicity. Analysis models that enable borrowing of information in this situation correspondingly
will present (dis)advantages over those not permitting borrowing at all. We are thus much con-
cerned with the accuracy of posterior estimates based on the proposed Bayesian model compared
with its alternatives. In the simulation study, we preserve the point estimates (posterior medians)
by the end of the completed trials, which may be a subset of or the entire 1000 pairs. We average
across such point estimates per human dose under the analysis models A – E to approximate the
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